[ad_1]
(Reuters) – Sienna Biopharmaceuticals Inc. said Monday that two pivotal trials to test its main experimental treatment for acne have not achieved their primary goals, sending its actions peak near 28 Topical treatment, SNA-001, administered after laser treatment to patients with moderate to severe acne vulgaris has not shown additional benefit in reducing inflammatory lesions , compared to those in the control group. "We are disappointed with these results, which have not confirmed the results of the previous proof of concept study," said Frederick Beddingfield in a statement. Third acne trials are expected in the fourth quarter of 2018, with the treatment being tested separately as a therapy to reduce unwanted mild pigmented hair, the company said.
Sienna's shares, which went public about a year ago, were down 22.9 percent to $ 12.11 in pre-market trading.
(Report by Tamara Mathias to Bengaluru, edited by Shailesh Kuber and Anil D & # 39; Silva)
[ad_2]
Source link
